Posted by Michael Wonder on 19 Aug 2019
Quebec becomes first province to list Lonsurf (trifluridine/tipiracil) for public reimbursement for adult patients with metastatic colorectal cancer
19 August 2019 - Cancer treatment taken orally shown to extend overall survival in patients whose disease has progressed following treatment with standard therapies.
Taiho Pharma Canada today announced that Quebec is the first province to make Lonsurf accessible with reimbursement under the Régie de l'assurance maladie du Québec (RAMQ).
This critical listing follows a positive clinical recommendation by the Institut national d'excellence en santé et en services sociaux (INESSS) recommending that the Minister include Lonsurf (trifluridine and tipiracil [as tipiracil hydrochloride] tablets) on the List of Medications for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have failed on previous standard therapies.
